Actively Recruiting
Evaluating Alternating Cycles of Chemoimmunotherapy and Pemigatinib for Advanced FGFR2-Positive Biliary Tract Cancer
Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-09-10
29
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment approach for adults with biliary tract cancer that cannot be removed by surgery and has spread locally or to other parts of the body. The study focuses on patients whose tumors have specific FGFR2 gene alterations. This phase II trial aims to assess the effectiveness and safety of alternating cycles of chemoimmunotherapy and an FGFR inhibitor in this patient group. Participants receive two alternating treatment blocks. The chemoimmunotherapy block involves cisplatin and gemcitabine given intravenously on days 1 and 15, with durvalumab administered intravenously on day 1, repeated every 28 days for two cycles. The FGFR inhibitor block consists of oral pemigatinib given daily for 14 days, repeated every 21 days for three cycles. Depending on disease progression and tolerance, patients may continue on either treatment or switch blocks, with options for maintenance therapy or discontinuation based on response. Throughout the study, patients undergo CT or MRI scans and provide blood samples to monitor tumor response and safety. Quality of life is also assessed using questionnaires. After treatment completion, patients are followed up at 30 days, then every 3 months for 2 years, and every 6 months up to 5 years. The main outcome measured is overall survival at 12 months, alongside tumor response, safety, and patient well-being over time.
CONDITIONS
Brief Title
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Research Team
T
The Ohio State University Comprehensive Cancer Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here